Latest Biotech News

St. Jude Children’s Research Hospital published a new method to better detect small off‑target changes produced by base editors, addressing a key safety challenge in precision genome editing. The...

A team reported an Adjustable RNA Information Manipulation (AIM) platform that uses a single‑strand deaminase to enable precise, site‑specific RNA editing, marking a step forward for transient...

Oregon Health & Science University researchers identified a drug combination—venetoclax (BCL2 inhibitor) plus palbociclib (CDK4/6 inhibitor)—that produced stronger, more durable anti‑leukemia...

A GWAS meta‑analysis of more than 640,000 individuals identified a rare noncoding variant, rs17834140‑T, that substantially lowers the risk of clonal hematopoiesis of indeterminate potential...

AbbVie signed a deal to acquire ex‑China rights to Zelgen Biopharmaceuticals’ trispecific T‑cell engager alveltamig (ZG‑006), committing $100 million up front and up to $1.075 billion in...

Insilico Medicine saw a strong post‑listing performance in Hong Kong, delivering a notable market gain that buoyed investor sentiment in AI‑drug discovery firms. The company’s listing was...

Roche appointed Harmeier to return as head of its venture fund, reversing a prior leadership change and signaling renewed focus on external innovation sourcing. The BioCentury management brief...

Outlook Therapeutics received a third complete response letter (CRL) from the U.S. FDA for its bevacizumab biosimilar ONS‑5010 for wet age‑related macular degeneration, prompting a sharp share...

Psithera Inc. completed a spinout from Roivant, rebranding and securing $47.5 million in Series A financing to advance small‑molecule programs against immune and inflammatory targets. The company...

Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform, enabling EirGenix to offer continuous perfusion and integrated...

Nido Biosciences announced closure following a disappointing midstage study readout for its lead neurological candidate, ending five years of operations. The company’s phase‑2 failure underscores...

Ultragenyx reported two failed phase‑3 trials in brittle bone disease and announced plans for significant cost‑cutting to rebalance its portfolio and preserve cash. The company’s decision follows...

The National Institutes of Health lost another senior leader as NINDS director Walter Koroshetz announced his departure, adding to a series of exits that leave several institutes under interim...

St. Jude Children’s Research Hospital released a new method to better identify small off‑target edits produced by base editors, addressing a key safety bottleneck in precision genome editing. The...

Researchers released two high-resolution methods this week that sharpen detection of off-target edits produced by DNA base editors. A tailored genome-wide assay (CHANGE-seq-BE) provides sensitive,...

A new study used directed evolution and extended guide RNAs to produce adenine base editors (ABEs) with improved targeting precision and reduced bystander editing. The team combined enzyme...

Two papers this week advance programmable RNA editing through single-strand deaminases. One Nature Biotechnology report describes a platform that simultaneously rewrites multiple bases within a...

Nature Biotechnology and related work report converging advances in antifungal delivery using self-assembling peptide micelles. One study shows a host-defense peptide mimic that self-assembles...

A large GWAS meta-analysis of more than 640,000 individuals identified a rare noncoding variant, rs17834140‑T, that reduces clonal hematopoiesis (CHIP) and lowers blood-cancer risk. The protective...

Transcenta Therapeutics granted EirGenix a non‑exclusive license to its HiCB (highly intensified continuous bioprocessing) platform, including continuous perfusion and integrated hybrid...